Publications

Wan S, Zhao E, Weissinger D, Krantz BA, Werba G, Freeman D, Khanna LG, Siolas D, Oberstein PE, Chattopadhyay PK et al..  2023.  Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.. Front Immunol. 14:1067352.

Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D.  2021.  Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy.. Cell Rep. 36(8):109578.

Yin L, Criscito MC, Stokar E, Siolas D, Haimovic A, Sicco KLo, Brinster NK.  2021.  Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis.. Am J Dermatopathol. 43(10):746-749.

Siolas D, Morrissey C, Oberstein PEliezer.  2020.  The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.. J Pancreatol. 3(3):121-131.

Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D.  2017.  Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.. Cancer Immunol Res. 5(3):182-190.

Siolas D, Hannon GJ.  2013.  Patient-derived tumor xenografts: transforming clinical samples into mouse models.. Cancer Res. 73(17):5315-9.

Liu-Sullivan N, Zhang J, Bakleh A, Marchica J, Li J, Siolas D, Laquerre S, Degenhardt YY, Wooster R, Chang K et al..  2011.  Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).. Oncotarget. 2(12):1254-64.

Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR et al..  2005.  Second-generation shRNA libraries covering the mouse and human genomes.. Nat Genet. 37(11):1281-8.

Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA.  2005.  Synthetic shRNAs as potent RNAi triggers.. Nat Biotechnol. 23(2):227-31.